LiquiSmart Lung
Ultra-sensitive ctDNA testing for non-small cell lung cancer — from a tube of blood. Rescue when tissue is QNS. Then repeat, to catch treatment resistance as it emerges — often before imaging shows progression. All 11 guideline genes, 2-day turnaround, on standard PCR your lab already runs.
11 genes. 114 variants. One test.
Comprehensive coverage of NSCLC markers — 99% of DNA mutations and >97% of gene fusions listed in NCCN guidelines (COSMIC v100). From a single 10 mL blood draw.
Resistance is invisible until it's already advanced.
LiquiSmart makes it visible.
Cancer evolves under therapy. Rebiopsy is invasive and often not feasible. Imaging lags biology by months. A serial ctDNA test turns a single snapshot into a molecular timeline — quantitatively (how much) and qualitatively (why).
On-target resistance
The drug target itself changes, reducing binding.
- EGFR T790M — classic after early-generation EGFR TKIs
- EGFR C797S — key mechanism after osimertinib
- ALK G1202R — kinase-domain mutation on ALK inhibitors
Bypass signalling
The cancer activates another route around the block.
- MET amplification — a common osimertinib bypass
- HER2 amplification — alternative growth signalling
- KRAS / BRAF / PIK3CA — downstream pathway activation
Interpret in context. A negative plasma result does not rule out resistance — some tumours shed little ctDNA, and histological transformation still needs tissue. Molecular findings are integrated with imaging, pathology and clinical assessment. Refs: ESMO NSCLC guideline (Hendriks 2023); Pascual 2022; Thress 2015; Mok 2017; Dagogo-Jack 2020.
Sensitivity that matches or beats NGS. 100% specificity.
Median panel-wide sensitivity (LoD95). Performance holds at low input, where most NGS workflows fail.
- Patient
- L.G.* · 71 years
- Diagnosis
- Stage IV NSCLC
- Sample
- Pleural biopsy — 10–15% tumor content
- Prior testing
- NGS & sequential PCR returned QNS
*Anonymised patient case.
LiquiSmart returned an actionable EGFR L858R mutation from the same low-content sample — enabling targeted therapy to begin immediately.
When the sample is small, the result still has to count.
L.G. presented with a large pleural effusion and pleural nodularity. Pleural fluid was aspirated, but the cell block had insufficient cellularity for molecular studies. A pleural biopsy confirmed NSCLC — but at 10–15% tumour content it was deemed quantity not sufficient for NGS or sequential PCR.
With no molecular result and limited options, L.G. was started on chemotherapy — which he did not tolerate well. LiquiSmart returned the driver in 34 hours from the same sample.
Launched in India
Extensively validated. Available now.
- Reagents developed under ISO 13485
- Assay clinically validated at CLIA-certified, CAP-accredited laboratory
- Independently validated by ONCO X for India · NABL accredited laboratory
- Consistent performance across MD Anderson, UPenn, MCW & Fred Hutch
- 77 clinical samples analysed across sites — pleural effusions, FNAs, FNA washes
- Setup and training in 3 days
Order LiquiSmart Lung.
Request kits, connect to our scientific team, or explore a lab partnership.
Contact ONCO X